Why Is Cyanokit So Hard to Find? [Explained for 2026]

If you work in emergency medicine, fire services, or hospital pharmacy, you already know the frustration: Cyanokit — the brand name for hydroxocobalamin IV, the gold-standard antidote for cyanide poisoning — has been difficult to source since late 2024. The American Society of Health-System Pharmacists (ASHP) has listed it as having "limited availability," and the shortage shows no clear end in sight heading into 2026.

Unlike most drug shortages that affect everyday outpatient prescriptions, the Cyanokit shortage hits emergency services and hospital emergency departments hardest. This drug isn't picked up at the corner pharmacy — it's stocked in ambulances, hospital emergency departments, ICUs, and by fire departments. When supply tightens, the consequences can be life-or-death.

What Is Cyanokit and Why Is It Critical?

Cyanokit contains hydroxocobalamin, a form of vitamin B12 that binds directly to cyanide ions in the bloodstream. Each hydroxocobalamin molecule neutralizes one cyanide ion by forming cyanocobalamin — a nontoxic compound excreted in the urine. This process restores the cell's ability to use oxygen, reversing the life-threatening cellular suffocation that cyanide causes.

Cyanide poisoning most commonly occurs in victims of closed-space fires — where burning synthetic materials (carpeting, foam, plastics) release hydrogen cyanide gas. Industrial accidents, laboratory exposures, and intentional poisoning are other sources. Without rapid antidote administration, high-dose cyanide exposure can be fatal within minutes.

The FDA approved Cyanokit in 2006, and since 2018, an expert consensus panel has identified hydroxocobalamin as the preferred cyanide antidote — particularly for smoke inhalation victims, where it's safer than the alternative (sodium nitrite + sodium thiosulfate, sold as Nithiodote) because it does not impair the blood's ability to carry oxygen.

Why Is Cyanokit in Shortage in 2026?

The current Cyanokit shortage stems from manufacturing quality issues at SERB Pharmaceuticals' contract manufacturer. Specifically, production was suspended due to an investigation into a quality defect involving concerns about sterility assurance and endotoxin content in certain batches.

The FDA has released some impacted batches after testing — with guidance that facilities may use a 0.2-micron in-line filter during administration as a temporary risk mitigation measure. However, overall supply remains constrained. Healthcare providers are advised to weigh the potential benefit of using available Cyanokit against the risk, given the nature of the quality concerns.

This situation was first flagged in late 2024, when the ASHP added Cyanokit to its Drug Shortage List with no anticipated resolution date from the manufacturer. By August 2025, the drug remained in limited availability.

What Makes This Shortage Particularly Dangerous?

Several factors make the Cyanokit shortage especially serious compared to other drug shortages:

• There is no generic version. Cyanokit is a brand-only product. There is no FDA-approved generic hydroxocobalamin IV formulation available as a direct substitute.
• It is a life-saving emergency drug. Cyanide poisoning progresses rapidly — victims can lose consciousness and suffer cardiac arrest within minutes. Having the antidote on hand before an emergency occurs is essential.
• The alternative antidote carries significant risks. Nithiodote (sodium nitrite + sodium thiosulfate) is the backup option, but sodium nitrite causes methemoglobinemia, which reduces blood oxygen capacity. This makes it potentially dangerous for the most common cyanide poisoning scenario — fire victims who also have carbon monoxide poisoning.
• Single-source vulnerability. With only one manufacturer producing Cyanokit, any production disruption immediately impacts the entire U.S. supply.

How Facilities Are Managing the Shortage

Emergency departments, hospital pharmacies, and EMS agencies are taking several approaches to manage limited supply:

1. Implementing shortage protocols. Some facilities are reserving available Cyanokit stock for confirmed or highly probable cyanide poisoning cases.
2. Using the 0.2-micron filter workaround. Per FDA guidance, administering available Cyanokit through a 0.2-micron in-line filter can help mitigate sterility concerns for batches with quality issues.
3. Stocking Nithiodote as a backup. Many facilities are ensuring they have Nithiodote available as an alternative, with updated treatment protocols that account for its limitations in smoke inhalation cases.
4. Actively sourcing available stock. Hospital pharmacy directors and EMS purchasing teams are reaching out to distributors and using services to locate facilities with available inventory.

Is Cyanokit Available at Retail Pharmacies?

No. Cyanokit is not a medication that is dispensed at retail pharmacies. It is an emergency IV antidote administered exclusively in clinical and prehospital settings — hospital emergency departments, intensive care units, and by paramedics and fire departments equipped to administer IV medications. It is procured through hospital pharmacy systems, medical distributors, and specialty emergency medicine suppliers.

How medfinder Can Help Locate Available Cyanokit Supply

For healthcare organizations and emergency services trying to locate available Cyanokit in their region, medfinder for providers offers a direct way to check which facilities and suppliers have Cyanokit in stock. Rather than making dozens of manual calls, our service contacts the relevant channels to find available supply — saving critical time when every minute counts.

For more guidance on managing the Cyanokit shortage, see our related posts on the Cyanokit shortage update and alternatives to Cyanokit when supply is unavailable.

What to Watch in 2026

As of early 2026, the Cyanokit shortage remains an active concern. Emergency medicine and toxicology societies continue to monitor the situation. Key things to watch:

• ASHP drug shortage updates for hydroxocobalamin for injection
• FDA safety communications regarding impacted batch numbers
• Updates from SERB Pharmaceuticals on manufacturing remediation timeline
• Regional poison control center guidance (1-800-222-1222) on alternative treatment protocols

The Cyanokit shortage is a serious public health issue. Ensuring that emergency departments and first responders have access to this critical antidote — or are prepared with effective alternatives — remains a top priority for emergency medicine professionals in 2026.